Pino Biologicals

PinotBio is a clinical-stage biotechnology company based in South Korea, specializing in the development of next-generation antibody-drug conjugates (ADCs) and innovative targeted therapies for cancer and glaucoma. The company’s flagship technology, PINOT-ADC™, is a proprietary platform utilizing camptothecin-based payloads and specific linkers designed to overcome drug resistance and improve safety profiles compared to existing treatments. PinotBio’s lead clinical candidate, NTX-301, is a small molecule inhibitor of DNA methyltransferase 1 (DNMT1) currently in Phase 1/2 trials for hematologic malignancies like AML and MDS. Through strategic partnerships with industry leaders such as Celltrion and Lotte Biologics, the company is advancing a robust pipeline of ADC candidates targeting diverse markers like cMET, Nectin-4, and Trop2.